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Abstract
Keratocan is an extracellular matrix protein that belongs to the small leucine-rich proteoglycan
family which also includes the lumican, biglycan, decorin, mimecan and fibromodulin. Members
of this family are known to play a role in regulating cellular processes such as proliferation and
modulation of osteoprogenitor lineage differentiation. The aims of this study were to evaluate the
expression pattern of the keratocan within the osteoprogenitor lineage and assess its role in
regulating osteoblast maturation and function. Results from gene expression analyses of cells at
different maturation stages within the osteoblast lineage indicate that keratocan is differentially
expressed by osteoblasts and shows little or no expression by osteocytes. During primary
osteoblast cultures, high keratocan mRNA expression was observed on day 14, while lower
expression was detected at days 7 and 21. To assess the effects of keratocan on osteoprogenitor
cell differentiation, we evaluated primary calvarial cell cultures from keratocan deficient mice.
The mineralization of calvarial osteoblast cultures derived from keratocan null (kera−/−) mice was
lower than in wild type osteoblast cultures. Furthermore, analysis of RNA derived from kera−/−
calvarial cell cultures showed a reduction in the mature osteoblast differentiation markers, i.e.,
bone sialoprotein (BSP) and osteocalcin (OC). In addition, we have evaluated the bone formation
in keratocan deficient mice. Histomorphometric analysis indicated that homozygous knockout
mice have a significantly decreased rates of bone formation rate and mineral apposition. Taken
together our results demonstrate the expression of keratocan by osteoblast lineage cells and its
ability to modulate osteoblast function.
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INTRODUCTION
Proteoglycans are among the non-collagen, extracellular matrix proteins present in the bone
tissue, and participate in collagen fibrillogenesis [1; 2; 3]. Studies of the gene expression
profile of proteoglycans in bone have generated insights into their specific functions during
osteoblast maturation [4; 5]. Keratocan is a member of the small, leucine-rich, proteoglycan
family (SLRP) [6; 7]. SLRPs are extracellular matrix (ECM) molecules that contain a
tandem array of leucine-rich repeat (LRR) motifs flanked by conserved cysteine residues in
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N-and C-terminal domains of the core proteins [8]. SLRPs are divided into three classes
based on the spacing of their N-terminal cysteines, the number of LRRs they contain, and
their corresponding gene structures. Class I (decorin, biglycan, and asporin) and class II
SLRPs (fibromodulin, proline/arginine-rich end leucine-rich repeat protein (PRELP),
keratocan, lumican, and osteoadherin/osteomodulin) contain 10–12 LRRs, whereas class III
SLRPs (EPN/PG-Lb/DSPG3, opticin, and osteoglycin/mimecan) contain 6–8 LRRs [9].
SLRPs members, biglycan and decorin have been found in many skeletal regions including
articular and epiphyseal cartilage, and the periosteum [10]. Mice lacking biglycan and
decorin demonstrated the importance of the effects of microenvironment on stem cells. The
phenotype of mice doubly deficient in both biglycan and decorin can be attributed to
deregulation of transforming growth factor beta (TGFβ) sequestration, resulting in the
increased apoptosis of osteoprogenitors [11]. In contrast, mice deficient in fibromodulin
have enhanced alveolar bone formation at postnatal days 0 and 7, but normal levels at day
21 [12].
The expression of keratocan has been reported in the cornea and thinner corneal stroma was
observed in keratocan deficient mice in comparison to wild-type littermates. As
demonstrated by transmission electron microscopy, Kera−/− mice have larger stromal fibril
diameters and less organized packing of collagen fibrils in stroma than those of the wild type
animals [6]. These studies indicate that keratocan in cornea acts as a vital component in
collagen fibrillogenesis [13; 14]. Using immunohistochemistry keratocan was also detected
in tendon where it is likely to play a role in collagen fibrillogenesis [15].
Recently, using visual reporters of osteoblast lineage differentiation markers and microarray
analysis, we have observed the expression of keratocan in the population of cells expressing
the osteoblastic marker (Col2.3GFP) [5]. In this study, we investigated the role of keratocan
in osteoblast differentiation and function using keratocan deficient mice. Our result shows a
reduction in bone markers and decreased mineralization in primary calvarial osteoblast
cultures derived from kera−/− mice. Similarly in vivo evaluation of 3-month-old kera−/−
mice demonstrated decreases in both bone formation and mineral apposition rates. This
result suggests a role for keratocan in the normal expression of differentiation markers, i.e.,
bone sialoprotein (BSP) and osteocalcin (OC) by osteoblasts.
MATERIALS AND METHOD
Mouse Models—The 2.3 kb of rat type I collagen promoter fragment-cyan fluorescent
reporter (pOBCol2.3CFP) and dentin matrix protein 1- topaz fluorescent reporter (DMP-1-
GFP) mice have been previously developed and characterized [16; 17]. Mice deficient for
Keratocan (kera−/−) have been developed and characterized by Dr. Winston Kao [6].
Experimental mice were generated by breeding Kera+/− mice to produce all three genotypes
(kera−/−, kera+/−, and kera+/+). Different genotypes were identified using the following
primers kera-1, 5′-gatggcctagtcggccatcactgcaaagag-3′; kera-2, 5′-
cacccagagtattaaacagtttggggttgc-3′; neo(+), 5′-cgcttcctcgtgctttacggtatcgccgctc-3′. [6].
Calvarial Osteoblast Culture—Calvarial cells were isolated from 5–7 day-old neonatal
wild type and kera−/− mice using a modified version of the protocol developed by Wong
and Cohn [18; 19]. Calvaria were subjected to four, sequential, 30-min digestions in an
enzyme mixture containing 0.05% trypsin and 1.5 U/ml collagenase P at 37 °C. Cell
fractions 2–4 were pooled and enzyme activity was terminated by addition of culture media
(Dulbecco’s modified Eagle’s medium (DMEM) Life Technologies) supplemented with
10% FBS (Hyclone). Cells were plated at a density of 1.5 ×105 cells/well in 6-well culture
plates. Differentiation medium (αMEM, 10% FBS, 50 μg/ml ascorbic acid, 4 mM β-
glycerophosphate) was added when cells reached confluence, usually on day 7 after plating.
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Cells were harvested on days 7, 14 and 21 for RNA or stained for alkaline phosphatase
expression or mineralization.
Cell Separation Using Flow Cytometry Cell Sorting
Neonatal calvaria derived from 5–8 day old dual reporter transgenic mice (Col2.3CFP/
DMP-1GFP) were enzymatically digested using a procedure described above [5]. Cells were
sorted using a FACS Vantage (Becton Dickinson) cell sorter with appropriate lasers to
excite GFP at 488nm and CFP at 413nm. Details of the cell sorting procedure and isolation
of cells for RNA extraction have been previously described [5].
Histochemical Analysis of Cell Cultures—Histochemical staining for ALP activity
was performed using a commercially available kit (86-R, Sigma Diagnostics, Inc., MO,
USA) according to the manufacturer’s instructions. Mineralization was assessed using the
von Kossa silver nitrate staining method. The results of staining procedures were recorded
using a scanner (UMax Astra 4000U), and composite images were generated using Adobe
Photoshop.
RNA extraction—Total RNA was isolated from cell populations using TRIzol reagent
(Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions. Measurement
of RNA yield was performed using a NanoDrop 1000A Spectrophotometer (Thermo Fisher
Scientific, Waltham, MA, USA).
RT-PCR—Following the extraction and quantification procedure, RNA was subjected to
DNase treatment (DNase I, Invitrogen) to eliminate genomic DNA contamination. cDNA
was synthesized using an Invitrogen Superscript First-strand Synthesis System for RT-PCR.
TaqMan® Gene Expression Assays were purchased from ABI and real time PCR was
performed on the 7500 Real-Time PCR System (assay ID: Kera, Mm00515230_m1,
Osteocalcin, Mm03413826_mH, BSP, Mm00492555_m1, and ALP, Mm01187117).
GAPDH was used as internal control (Mm99999915_g1). Before using the ΔΔCT method
for quantification, validation experiments were performed to demonstrate that the
amplification efficiencies of target genes and the reference gene were approximately equal.
Northern blot—Total RNA (10 ug) was separated on a 2.2 M formaldehyde/1% agarose
gel and transferred onto a nylon membrane (Maximum Strength Nytran Plus, Schleicher &
Schuell). Membranes were probed with a 440 bp mouse OC fragment (p923) [20] and
mouse BSP [21]. Probes were radiolabeled by the random primer method using (α-32P)
dCTP (New England Nuclear, 3000 Ci/mmol) to obtain specific activities of approximately
1 × 109 cpm/μg. Filters were hybridized with 3 × 106 cpm/ml 32P-labeled probe at 42 °C in
50% formamide, 5x SSPE (1x SSPE = 0.149 M NaCl, 10 mM NaH2PO4, 1 mM EDTA, pH
7.4), 1.2x Denhardt’s and 0.5% sodium dodecyl sulfate and washed according to published
procedures [22].
Bone histomorphorphometric analysis
To perform dynamic histomorphometry, 3-month-old mice were injected intraperitoneally
with 10 mg/kg of calcein and 90 mg/kg of xylenol orange. Calcein was injected 7 days
before animals were sacrificed, while xylenol orange was injected2 days before sacrifice.
The femurs were fixed in 10% formalin at 4 °C, and immobilized in embedding media
(Cryomatrix, Thermo Shandon, Pittsburgh). The embedded bones were longitudinally
sectioned in 5 μm thick sections using CryoJane tape system (Instrumedics, NJ USA).
Sections were covered in 50%glycerol/PBS and dynamic histomorphometry was completed
using the Osteomeasure system (OsteoMetrics, Inc., Atlanta, GA). Measurements were
completed within the trabecular region region 400μm away from growth plate and 225μm
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away from both sides of the endocortical suface. The measurements, terminology, and
unitsused for histomorphometry were basedon the convention of standardized nomenclature
[23].
Immunohistochemistry—Calvaria from 6 weeks old mice were fixed for 3 days in 4%
paraformaldehyde/PBS (pH 7.4) at 4°C, decalcified for 3 days, placed in 30% sucrose/PBS
overnight, and embedded. For immunohistochemistry, 5 μm cryosections were briefly
rinsed in PBS, blocked with 5% normal serum in 1% BSA/PBS for 1 hour, and then
incubated overnight with rabbit polyclonal anti-keratocan (SC-66941, Santa Cruz Biotech,
CA, USA). Signal was detected with Envision System HRP (DAB) (Dakoctomation,
Carpinteria, CA), sections were counter stained with hematoxylin and imaged with a
microscope equipped with a CCD camera.
RESULTS
Keratocan expression in cells of the osteoblast lineage
To demonstrate the expression of keratocan by osteoblast lineage cells, we performed real
time PCR analysis of RNA derived from freshly isolated osteoblasts and osteocytes obtained
from neonatal calvaria at postnatal days 5–8. We utilized previously established GFP
transgenic mice in which defined stages of osteoblast differentiation were marked by
expression of specific variants of GFP protein (Fig. 1A). The Col2.3 promoter directs the
expression to osteoblasts and osteocytes, while DMP-1 promoter can be used to identify
preosteocytes and osteocytes. Using a combination of different variants of GFP stage
specific cell population can be separated [5; 22]. Osteoblasts and osteocytes were separated
using flow cytometry cell sorting as described previously [5]. Gates utilized for cell sorting
are shown in Figure 1B, and purity of the sorted population was confirmed by re-analysis
(Fig. 1C–E). Analysis of gene expression using real time PCR demonstrated the strong
expression of keratocan by mature osteoblasts (Fig. 1F, CFP+ group), while a weak signal
was observed in the group that corresponds to osteocytes (Figure 1F, GFP+ group). This
finding was confirmed during differentiation of primary calvarial osteoblast cultures, i.e. we
detected peak mRNA levels of keratocan mRNA at day 14 of culture, while lower
expression was observed at days 7 and 21 respectively (Fig. 1G). By day 14 osteoprogenitor
cells differentiate into mature osteoblasts that express established markers characteristic of
matrix producing bone cells. We compared the level of keratocan expression in bone to
other tissues that have been shown to express high keratocan levels. The expression of
keratocan in bone was three-fold lower than in corneal-containing eye tissue. Keratocan
expression was not detected in the sample of lung that we have utilized as negative control
(Fig. 1H).
Having determined that keratocan mRNA is present in osteoblasts, we analyzed keratocan
expression at the protein level. Consistent with the mRNA results, keratocan protein was
detected in osteoblasts as demonstrated by immunohistochemistry (Figure 2), Keratocan
expression was observed in the osteoblast lining the periosteal and endosteal surfaces.
Analysis of bone formation in Kera deficient Mice
We performed histomorphormetric analysis on bone tissues derived from 3-month-old wild
type and keratocan knockout mice. Our results demonstrate a significant decrease in the
mineral apposition rate (MAR) (Fig. 3A, P=0.05) in femurs derived from keratocan deficient
mice compared to samples derived from wild type control littermates. Furthermore, the bone
formation rate was significantly decreased in kera−/− mice when compared to the wild type
(Fig. 3B, p= 0.007). Mice heterozygous for keratocan also had both MAR and BFR closer to
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the levels of the complete knockout. Mineralizing surface also showed a decreasing trend in
Kera−/− mice compared to wild type mice.
Effects of Keratocan deficiency on osteoprogenitor differentiation In vitro
The histomorphometric observation prompted us to evaluate whether we could explain the
results by studying the phenotype of osteoblast cells isolated from the calvaria (parietal
bones) of kera−/− mice. Primary calvarial osteoblasts cultures from kera−/− mice showed
detectable differences in the expression of ALP compared to wild type (Figure 4A, D).
Decreased mineral deposition, as detected by von Kossa staining, was observed on day 21 of
culture (Figure 4B). In addition, Northern blot analysis of RNA demonstrated decreased
expression of mature osteoblast markers like bone sialoprotein and osteocalcin at 21 days of
culture in cells obtained from kera−/− mice (Figure 4C, D). Results obtained in vitro are in
line with the observation that keratocan is preferentially expressed in osteoblasts. Therefore,
we did not expect to find significant changes in osteogenic parameters until the lineage
maturation reached the osteoblast stage.
DISCUSSION
This study confirms that keratocan is expressed in bone, as demonstrated by the presence of
keratocan mRNA and protein in mature osteoblasts. Keratocan is a member of the small,
leucine-rich, proteoglycan family (SLRP). This family includes lumican, decorin, and
biglycan[24]. During embryonic development members of this family have been reported to
participate in bone development [10]. Interestingly, we observed the highest expression of
keratocan in mature osteoblasts as compared to osteoprogenitors and osteocytes. Mature
osteoblasts are very active in the bone formation process, synthesizing and secreting
collagenous and non-collagenous proteins. The expression of SLRPs in osteoblast lineage
cells in culture tends to follow a pattern corresponding to their reported function or role in
bone development. For instance, while biglycan was detected in forming growth plates,
fibromodulin, a closely related homologue to keratocan, was detected at the primary
ossification center [25]. Also, biglycan and fibromodulin were highly expressed in the disc
and articular cartilage of the temporomandibular joint (TMJ) [26], and therefore, mice
deficient in both biglycan and fibromodulin developed accelerated osteoarthritis with visible
small vertical clefts in the condylar cartilage and partial disruption of the disk [26; 27]. It has
been previously demonstrated that ablation of the Kera gene resulted in subtle structural
alterations of the collagenous matrix in the mouse cornea, suggesting that keratocan might
play a role in maintaining the appropriate corneal shape to ensure normal vision [6]. We
have investigated whether keratocan plays any role in the bone tissue.
We observed decreased expression of osteoblast differentiation markers in day 21 calvarial
osteoblasts derived from a keratocan−/− mice. It is intriguing that at day 21 of culture,
osteoblasts from kera−/− mice demonstrated decreased mineral deposition. This observation
suggests that keratocan is important at the mature osteoblast stage. In addition, In vivo
results obtained by dynamic histomorphometry showed decreased MAR and BFR in kera−/−
mice compared to wild type. Mice heterozygous for the keratocan mutation exhibited MAR
and BFR changes similar to the complete knockout. We could speculate that this finding
may suggest that there is a critical amount of the keratocan necessary for proper osteoid
formation. Indeed, during in vitro differentiation markers of osteogenic differentiation were
not different between kera+/+ and kera+/−. This difference of the effects of keratocan
deficiency In vivo and In vitro, could be due to the lack of effect of microenvironment or
other cell lineages in an In vitro system. During bone formation, mature osteoblasts are
known to synthesize and secrete high levels of collagen, which is critical step preceding
collagen fibrillogenesis. Previously, the role of keratocan in collagen fiber formation has
been documented [28]. Based on our observation of decreased mineral apposition rate in the
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keratocan deficient mouse, it can be hypothesized that keratocan participates in the
formation of osteoid. Collagen fibers are well ordered within the osteiod, and disruption of
this order may lead to alterations in the subsequent mineralization of osteoid. Further studies
will be required to characterize the molecular mechanism of keratocan in osteoblast function
and activity.
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Figure 1. Detection of Keratocan mRNA in osteoblast lineage cells
(A) Transgenic constructs used to generate Dmp1-GFPtopaz (GFP) and Col2.3GFPcyan
(CFP). (B) Isolation of cell populations based on visual transgene expression was completed
using flow cytometry with sorting gates that clearly define populations (P2, DMP-1GFP+;
P3, Col2.3CFP+; P4, Dmp-1GFP-/Col2.3CFP-). Reanalysis of the isolated population of
GFP- cells (C), CFP+ (D) and GFP+ (E).
(F) Keratocan expression in freshly isolated calvarial osteoblasts and osteocytes obtained
from dual transgenic mice (DMP-1topaz/Col2.3cyan). Higher expression of keratocan was
observed in the Col2.3CFP positive population than in the DMP-1GFP positive cells. Four
biological replicates were analyzed by real time PCR. (G) Real time PCR detection of
keratocan mRNA in primary mouse calvarial osteoblast cultures. Keratocan was highly
expressed on day 14 compared to earlier (day 7) or later (day 21) time points. (H) Real time
PCR detection of keratocan mRNA in samples derived from bone, lung and eye.
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Figure 2. Detection of keratocan protein by immunohistochemistry
(A–B) Cryosections of calvarial bone harvested from 4-week-old mice were immunostained
for keratocan and counterstained with hematoxylin. The left panel (A) shows a negative
control without primary antibody. Right panel (B) shows alternate section stained with
primary anti keratocan antibody. Keratocan expression was observed in osteoblasts lining
bone surfaces (B, arrows indicate osteoblast layer; cb, cortical bone).
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Figure 3. Dynamic histomorphometric analysis of Kera−/− mice
Frozen sections were obtained from 3 months old male kera−/− (n=5), kera+/− (n=7) and
wild type littermates (n=8). Mice received an i.p. injection of calcein and following 5 days
interval they were injected i.p. with xylenol orange. Sections were analyzed for
histomorphometric parameters (A) Mineral apposition rate (MAR, μm/day), (B) Bone
formation rate/bone surface (BFR/BS, μm3/μm2/day) and (C) Mineralizing surface, %.
Values represent mean ± SD, *p≤0.05. (D) Representative images of Calcein-Xylenol
orange in the trabecular region of kera+/+ and Kera−/−.
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Figure 4. Decreased differentiation of primary osteoblasts derived from kera−/−mice
A) Alkaline phosphatase expression (days 7–21) and mineralization (day 14–21) were
analyzed using Von Kossa method (black spots) during calvarial osteoprogenitor cell
differentiation in vitro. A representative of three biological experiments is shown. (B)
mCOB cells derived from kera−/− show decreased mineralization while heterozygous mice
did not show significant change in the mineralization, * p≤0.05). C) Following osteogenic
induction osteocalcin and bone sialoprotein expression in mCOB cultures derived from kera
−/− mice were analyzed by Northern blot analysis. A decrease in both bone sialoprotein and
osteocalcin is observed on day 21 in kera−/−, compared to wild type (kera+/+) mice. D)
Real time PCR analysis of mRNA expression for ALP, BSP and OC (results presented in
figure 4D are technical replicates derived from one of two experiments;
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